Management of clozapine-resistant schizophrenia

Advances in Psychiatric Treatment

Volumn 11, Issue 2, 2005, Pages 101-106

  Kerwin, Rob W ^a   Bolonna, Anusha ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LAMOTRIGINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TOPIRAMATE;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; INCIDENCE; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 14744304526     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.11.2.101     Document Type: Article

References (39)

1. Aitchison, K. J., Jann, M. W., Zhao, J. H., et al (2000) Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. Journal of Psychopharmacology, 14, 353-359.
2. Barnes, T. R. E., McEvedy, C. J. B. & Nelson, H. E. (1996) Management of treatment resistant schizophrenia unresponsive to clozapine. British Journal of Psychiatry, 169 (suppl. 31), 31-40.
3. Bondolfi, G., Dufour, H., Patris, M., et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. American Journal of Psychiatry, 155, 499-504.
4. Brambilla, P., Barale, F. & Caverzasi, E. (2002) Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. International Journal of Clinical Psychopharmacology, 17, 189-195.
5. Brooks, J. O. III (2001) Successful outcome using quetiapine in a case of treatment resistant schizophrenia with assaultive behaviour. Schizophrenia Research, 50, 133-134.
6. Conley, R. R., Tamminga, C. A., Bartko, J. J., et al (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155, 914-920.
7. Conley, R. R., Tamminga, C. A., Kelly, D. L., et al (1999) Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry, 46, 73-77.
8. Connolly, M. & Kelly, C. (2005) Lifestyle and physical health of people with schizophrenia. Advances in Psychiatric Treatment, 11, 125-132.
9. Dursun, S. M. & Deakin, J. F. (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Journal of Psychopharmacology, 15, 297-301.
10. Dursun, S. M., Gardner, D. M., Bird, D. C., et al (1999) Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Canadian Journal of Psychiatry 44, 701-704.
11. Fabre, L. F., Arvanitis, J., Pultz, V. M., et al (1995) ICI 204-636 a novel atypical antipsychotic: early indications of safety and efficacy in patients with chronic and subchronic schizophrenia. Clinical Therapeutics, 17, 366-378.
12. Gopal, Y. V. & Variend, H. (2005) First-episode schizophrenia: review of cognitive deficits and cognitive remediation. Advances in Psychiatric Treatment, 11, 38-44.
13. Iqbal, M. M., Rahman, A., Husain, Z., et al (2003) Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry, 15, 33-48.
14. Juarez-Reyes, M. G., Shumway, M., Battle, C., et al (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 46, 801-806.
15. Kane, J. M. (1992) Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. British Journal of Psychiatry, 160 (suppl. 17), 41-45.
16. Kane, J. M. (1996) Factors which make patients difficult to treat. British Journal of Psychiatry, 169 (suppl. 31), 10-14.
17. Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
18. Kerwin, R. W. (2000) From pharmacological profiles to clinical outcomes. International Journal of Clinical Psychopharmacology, 15, S1-S4.
19. Kerwin, R. W. & Osborne, S. (2000) Antipsychotic drugs. Medicine, 28, 23-25.
20. Leask, S. J. (2004) Environmental influences in schizophrenia: the known and the unknown. Advances in Psychiatric Treatment, 10, 323-330.
21. Lerner, V., Libov, I., Kotler, M., et al (2004) Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 28 89-98.
22. Lindenmayer, J. P., Czobor, P. & Volavka, J. (2002) Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Journal of Clinical Psychiatry, 63, 931-935.
23. Ma, J. D., Nafziger, A. N. & Bertino, J. S. Jr. (2004) Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. Journal of Clinical Pharmacology, 44, 447-456.
24. McCreadie, R. G. (2004) Editorial: Schizophrenia revisited. Advances in Psychiatric Treatment, 10, 321-322.
25. Meltzer, H. Y. (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18, 515-542.
26. Morrison, D. P. (1996) Management of treatment refractory schizophrenia. British Journal of Psychiatry, 169 (suppl. 31), 15-20.
27. Munro, J., Matthiasson, P., Osborne, S., et al (2004) Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatrica Scandinavica, 110, 292-298.
28. National Institute for Clinical Excellence (2002) Clinical Guideline 1. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE.
29. Pantelis, C. & Lambert, T. J. (2003) Managing patients with "treatment-resistant" schizophrenia. Medical Journal of Australia 178 (suppl.), S62-S66.
30. Perry, P. J., Miller, D., Arndt, S. V., et al (1991) Clozapine concentrations and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. American Journal of Psychiatry, 148, 231-235.
31. Potkin, S. G., Bera, R., Gulaskeram, B., et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 55 (suppl. B), 133-136.
32. Rowlands, P. (2004) The NICE schizophrenia guidelines: the challenge of implementation. Advances in Psychiatric Treatment, 10, 403-412.
33. Shiloh, R., Zemishlany, Z., Aizenberg, D., et al (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry, 171, 569-573.
34. Singh, S. P. & Fisher, H. L. (2005) Early intervention in psychosis: obstacles and opportunities. Advances in Psychiatric Treatment, 11, 71-78.
35. Tiihonen, J., Hallikainen, T., Ryynanen, O. P., et al (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry, 54 1241-1248.
36. Tsapakis, E., Basu, A. & Aitchison, K. J. (2004) Clinical relevance of discoveries in psychopharmacogenetics. Advances in Psychiatric Treatment, 10, 455-465.
37. Wahlbeck, K., Cheine, M., Essali, A., et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry, 156, 990-999.
38. Wahlbeck, K., Cheine, M. & Tuisku, K. (2000) Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry 24, 911-922.
39. Zink, M., Knopf, U., Henn, F. A., et al (2004) Combination of clozapine and amisulpride in treatment-resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry, 37, 26-31.